Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma

A Phase II Study

Mohammad Jahanzeb, Greg Sarna, Robert Hirsch, Peter Radice, Alan Koletsky, Manuel Martinez, Elena Kruglyak, Edward Wolin, Elber Camacho, Lori Kronish, Susannah Motl

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Taxanes have been widely used against advanced non-small cell lung cancer (NSCLC), alone and in combination with platinum agents. In order to develop a tolerable palliative regimen, we combined carboplatin with low dose docetaxel. Patients and Methods: Chemotherapy-naive patients, with Stage IIIB or IV NSCLC and an ECOG performance status ≤2, were enrolled Treatment consisted of docetaxel 60 mg/m2 and carboplatin AUC 6 every 21 days. Therapy continued for 1 year or 6 months beyond best response, whichever was greater. Results: Twenty-five patients were enrolled. Most patients (80%) had Stage IV disease. The partial response rate was 16%. Response duration ranged from 6 to 115 weeks. Median survival was 55 weeks. Toxicity was generally limited to grade 3 or 4 neutropenia. There was 1 septic death. Conclusion: Survival compared favorably to other similar trials employing higher doses of docetaxel Additionally, a hematologic toxicity advantage was seen compared to regimens containing higher doses of docetaxel.

Original languageEnglish (US)
Pages (from-to)1239-1242
Number of pages4
JournalAnticancer Research
Volume24
Issue number2 C
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

docetaxel
Carboplatin
Non-Small Cell Lung Carcinoma
Taxoids
Survival
Therapeutics
Neutropenia
Platinum
Area Under Curve
Drug Therapy

Keywords

  • Carboplatin
  • Docetaxel
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jahanzeb, M., Sarna, G., Hirsch, R., Radice, P., Koletsky, A., Martinez, M., ... Motl, S. (2004). Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study. Anticancer Research, 24(2 C), 1239-1242.

Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma : A Phase II Study. / Jahanzeb, Mohammad; Sarna, Greg; Hirsch, Robert; Radice, Peter; Koletsky, Alan; Martinez, Manuel; Kruglyak, Elena; Wolin, Edward; Camacho, Elber; Kronish, Lori; Motl, Susannah.

In: Anticancer Research, Vol. 24, No. 2 C, 03.2004, p. 1239-1242.

Research output: Contribution to journalArticle

Jahanzeb, M, Sarna, G, Hirsch, R, Radice, P, Koletsky, A, Martinez, M, Kruglyak, E, Wolin, E, Camacho, E, Kronish, L & Motl, S 2004, 'Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study', Anticancer Research, vol. 24, no. 2 C, pp. 1239-1242.
Jahanzeb M, Sarna G, Hirsch R, Radice P, Koletsky A, Martinez M et al. Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study. Anticancer Research. 2004 Mar;24(2 C):1239-1242.
Jahanzeb, Mohammad ; Sarna, Greg ; Hirsch, Robert ; Radice, Peter ; Koletsky, Alan ; Martinez, Manuel ; Kruglyak, Elena ; Wolin, Edward ; Camacho, Elber ; Kronish, Lori ; Motl, Susannah. / Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma : A Phase II Study. In: Anticancer Research. 2004 ; Vol. 24, No. 2 C. pp. 1239-1242.
@article{8571554b3c574b9e9523e7da3c07f8d1,
title = "Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study",
abstract = "Background: Taxanes have been widely used against advanced non-small cell lung cancer (NSCLC), alone and in combination with platinum agents. In order to develop a tolerable palliative regimen, we combined carboplatin with low dose docetaxel. Patients and Methods: Chemotherapy-naive patients, with Stage IIIB or IV NSCLC and an ECOG performance status ≤2, were enrolled Treatment consisted of docetaxel 60 mg/m2 and carboplatin AUC 6 every 21 days. Therapy continued for 1 year or 6 months beyond best response, whichever was greater. Results: Twenty-five patients were enrolled. Most patients (80{\%}) had Stage IV disease. The partial response rate was 16{\%}. Response duration ranged from 6 to 115 weeks. Median survival was 55 weeks. Toxicity was generally limited to grade 3 or 4 neutropenia. There was 1 septic death. Conclusion: Survival compared favorably to other similar trials employing higher doses of docetaxel Additionally, a hematologic toxicity advantage was seen compared to regimens containing higher doses of docetaxel.",
keywords = "Carboplatin, Docetaxel, Non-small cell lung cancer",
author = "Mohammad Jahanzeb and Greg Sarna and Robert Hirsch and Peter Radice and Alan Koletsky and Manuel Martinez and Elena Kruglyak and Edward Wolin and Elber Camacho and Lori Kronish and Susannah Motl",
year = "2004",
month = "3",
language = "English (US)",
volume = "24",
pages = "1239--1242",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 C",

}

TY - JOUR

T1 - Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma

T2 - A Phase II Study

AU - Jahanzeb, Mohammad

AU - Sarna, Greg

AU - Hirsch, Robert

AU - Radice, Peter

AU - Koletsky, Alan

AU - Martinez, Manuel

AU - Kruglyak, Elena

AU - Wolin, Edward

AU - Camacho, Elber

AU - Kronish, Lori

AU - Motl, Susannah

PY - 2004/3

Y1 - 2004/3

N2 - Background: Taxanes have been widely used against advanced non-small cell lung cancer (NSCLC), alone and in combination with platinum agents. In order to develop a tolerable palliative regimen, we combined carboplatin with low dose docetaxel. Patients and Methods: Chemotherapy-naive patients, with Stage IIIB or IV NSCLC and an ECOG performance status ≤2, were enrolled Treatment consisted of docetaxel 60 mg/m2 and carboplatin AUC 6 every 21 days. Therapy continued for 1 year or 6 months beyond best response, whichever was greater. Results: Twenty-five patients were enrolled. Most patients (80%) had Stage IV disease. The partial response rate was 16%. Response duration ranged from 6 to 115 weeks. Median survival was 55 weeks. Toxicity was generally limited to grade 3 or 4 neutropenia. There was 1 septic death. Conclusion: Survival compared favorably to other similar trials employing higher doses of docetaxel Additionally, a hematologic toxicity advantage was seen compared to regimens containing higher doses of docetaxel.

AB - Background: Taxanes have been widely used against advanced non-small cell lung cancer (NSCLC), alone and in combination with platinum agents. In order to develop a tolerable palliative regimen, we combined carboplatin with low dose docetaxel. Patients and Methods: Chemotherapy-naive patients, with Stage IIIB or IV NSCLC and an ECOG performance status ≤2, were enrolled Treatment consisted of docetaxel 60 mg/m2 and carboplatin AUC 6 every 21 days. Therapy continued for 1 year or 6 months beyond best response, whichever was greater. Results: Twenty-five patients were enrolled. Most patients (80%) had Stage IV disease. The partial response rate was 16%. Response duration ranged from 6 to 115 weeks. Median survival was 55 weeks. Toxicity was generally limited to grade 3 or 4 neutropenia. There was 1 septic death. Conclusion: Survival compared favorably to other similar trials employing higher doses of docetaxel Additionally, a hematologic toxicity advantage was seen compared to regimens containing higher doses of docetaxel.

KW - Carboplatin

KW - Docetaxel

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=2442505868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442505868&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 1239

EP - 1242

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -